Leisure Capital Management Sells 2,921 Shares of Sanofi (NASDAQ:SNY)

Leisure Capital Management reduced its position in shares of Sanofi (NASDAQ:SNY) by 16.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,949 shares of the company’s stock after selling 2,921 shares during the period. Leisure Capital Management’s holdings in Sanofi were worth $721,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in SNY. Jennison Associates LLC lifted its position in shares of Sanofi by 938.0% during the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after buying an additional 1,720,972 shares in the last quarter. Thrivent Financial for Lutherans increased its position in shares of Sanofi by 28,890.2% during the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after acquiring an additional 1,424,289 shares during the last quarter. DAVENPORT & Co LLC lifted its holdings in Sanofi by 40.7% during the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after acquiring an additional 664,455 shares during the period. JPMorgan Chase & Co. boosted its position in Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after purchasing an additional 399,301 shares during the last quarter. Finally, Franklin Resources Inc. grew its stake in Sanofi by 13.1% in the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after purchasing an additional 395,744 shares during the period. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on SNY shares. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday. Finally, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $60.00.

Sanofi Trading Up 0.4 %

Shares of SNY opened at $54.34 on Monday. The firm has a market cap of $137.91 billion, a P/E ratio of 21.82, a price-to-earnings-growth ratio of 1.26 and a beta of 0.57. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.74 and a current ratio of 1.46. The business has a 50-day moving average of $49.24 and a 200 day moving average of $52.30.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. As a group, research analysts forecast that Sanofi will post 4.34 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.